PMID- 19622083 OWN - NLM STAT- MEDLINE DCOM- 20100217 LR - 20211020 IS - 1399-5448 (Electronic) IS - 1399-543X (Print) IS - 1399-543X (Linking) VI - 10 IP - 8 DP - 2009 Dec TI - An exploration of Glo-3A antibody levels in children at increased risk for type 1 diabetes mellitus. PG - 563-72 LID - 10.1111/j.1399-5448.2009.00541.x [doi] AB - AIMS: To determine whether Glo-3A, (formerly referred to as homologue of Glb1 or Glb1) antibodies are associated with islet autoimmunity (IA) in children at increased risk for type 1 diabetes (T1D) and to investigate their relation with environmental correlates of T1D. METHODS: We selected a sample from the Diabetes Autoimmunity Study in the Young (DAISY), a prospective study of children at increased risk for T1D. Cases were positive for insulin, glutamic acid decarboxylase (GAD), or insulinoma-associated antigen-2 (IA-2) autoantibodies on two consecutive visits and either diagnosed with diabetes mellitus or still autoantibody positive when selected. Controls were from the same increased risk group, of similar age as the cases but negative for autoantibodies. Sera from 91 IA cases and 82 controls were analyzed in a blinded manner for immunoglobulin G (IgG) antibodies to Glo-3A by ELISA. RESULTS: Adjusting for family history of T1D and human leukocyte antigen (HLA)-DR4 positivity, Glo-3A antibodies were not associated with IA case status (OR: 1.01, 95% CI: 0.99-1.03). Adjusting for age, family history of T1D, and HLA-DR4 positivity, Glo-3A antibody levels were inversely associated with breast-feeding duration (beta = -0.08, p = 0.001) and directly associated with current intake of foods containing gluten (beta = 0.24, p = 0.007) in IA cases but not in controls. Zonulin, a biomarker of gut permeability, was directly associated with Glo-3A antibody levels in cases (beta = 0.73, p = 0.003) but not in controls. CONCLUSION: Differing correlates of Glo-3A antibodies in IA cases and controls suggest an underlying difference in mucosal immune response. FAU - Simpson, M AU - Simpson M AD - Department of Epidemiology, Colorado School of Public Health, Colorado, USA. FAU - Mojibian, M AU - Mojibian M FAU - Barriga, K AU - Barriga K FAU - Scott, F W AU - Scott FW FAU - Fasano, A AU - Fasano A FAU - Rewers, M AU - Rewers M FAU - Norris, J M AU - Norris JM LA - eng GR - R01 DK032493-16/DK/NIDDK NIH HHS/United States GR - R01 DK050979/DK/NIDDK NIH HHS/United States GR - R01 DK049654/DK/NIDDK NIH HHS/United States GR - R01 DK049654-03/DK/NIDDK NIH HHS/United States GR - R01 DK032493/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20090720 PL - Denmark TA - Pediatr Diabetes JT - Pediatric diabetes JID - 100939345 RN - 0 (Autoantibodies) RN - 0 (Haptoglobins) RN - 0 (ICA512 autoantibody) RN - 0 (Immunoglobulin G) RN - 0 (Protein Precursors) RN - 0 (zonulin) RN - 9007-90-3 (Gliadin) RN - 9012-63-9 (Cholera Toxin) RN - EC 4.1.1.15 (Glutamate Decarboxylase) SB - IM MH - Autoantibodies/*blood MH - Celiac Disease/*epidemiology/*immunology MH - Child MH - Child, Preschool MH - Cholera Toxin/metabolism MH - Diabetes Mellitus, Type 1/*epidemiology/*immunology MH - Female MH - Gliadin/immunology MH - Glutamate Decarboxylase/immunology MH - Haptoglobins MH - Humans MH - Immunoglobulin G/blood MH - Infant MH - Intestinal Absorption/immunology MH - Islets of Langerhans/immunology MH - Male MH - Prospective Studies MH - Protein Precursors MH - Risk Factors MH - Seroepidemiologic Studies PMC - PMC2814050 MID - NIHMS171434 EDAT- 2009/07/23 09:00 MHDA- 2010/02/18 06:00 PMCR- 2010/12/01 CRDT- 2009/07/23 09:00 PHST- 2009/07/23 09:00 [entrez] PHST- 2009/07/23 09:00 [pubmed] PHST- 2010/02/18 06:00 [medline] PHST- 2010/12/01 00:00 [pmc-release] AID - PDI541 [pii] AID - 10.1111/j.1399-5448.2009.00541.x [doi] PST - ppublish SO - Pediatr Diabetes. 2009 Dec;10(8):563-72. doi: 10.1111/j.1399-5448.2009.00541.x. Epub 2009 Jul 20.